Impact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00486915|
Recruitment Status : Unknown
Verified June 2011 by London Health Sciences Centre.
Recruitment status was: Recruiting
First Posted : June 15, 2007
Last Update Posted : June 23, 2011
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Thromboembolism Cerebrovascular Accident||Procedure: Left Atrial Appendage Ligation||Not Applicable|
In patients with non-rheumatic atrial fibrillation, the left atrial appendage is the origin of at least 90% of all left atrial clots, and the resulting systemic emboli cause approximately 25% of all strokes. The stroke rate in patients with atrial fibrillation older than 75 years of age is 8.1% per year with one clinical risk factor and is 12% per year at any age in clinical trial populations with a history of prior thromboembolism. Three-year stroke rates in elderly nursing home patients not anticoagulated are in excess of 50% (Atrial Fibrillation Investigators 1994). Anticoagulation is oftentimes withheld due to the perception of excessive risk in case of a fall; even when anticoagulation is prescribed, it is well known that therapeutic levels are not always maintained.
Left atrial appendage obliteration is commonly performed in a variety of cardiac surgical operations. There have been animal studies and theoretical arguments which demonstrate the importance of the atrial appendage in its role to support cardiac output and blood pressure, and modulate thirst and hypercoagulability (Stollberger 2003); however this has been poorly studied and documented in humans in the available literature. BNP and ANP have been shown to increase proportionately with left atrial appendage dysfunction, as have von Willebrands Factor, D-Dimer, and thrombin-antithrombin III complex (Igarashi 2001).
To date, there is not a single randomized controlled trial with adequate follow-up to assess the short- and long-term clinical effectiveness of concurrent prophylactic LAA ligation. This trial will fill that void.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Concurrent Prophylactic Left Atrial Appendage Exclusion: A Randomized Controlled Trial|
|Study Start Date :||April 2007|
|Estimated Study Completion Date :||December 2011|
|Active Comparator: Left Atrial Appendage Exclusion||
Procedure: Left Atrial Appendage Ligation
|No Intervention: Control|
- Incidence of Stroke [ Time Frame: 4 years ]
- Short- and Long-term biochemical parameters
- Short-term clinical outcomes (Procedural complications, hospital length of stay, etc)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00486915
|Hospital San Rafael||Recruiting|
|Milan, MI, Italy|
|Principal Investigator:||Dave Nagpal, MD||London Health Sciences Centre|
|Principal Investigator:||Lucia Torracca, MD||Hospital San Rafael|
|Study Director:||Ottavio Alfieri, MD||Hospital San Rafael|